Switching tumour necrosis factor α antagonists in patients with ankylosing spondylitis and psoriatic arthritis: An observational study over a 5-year period

Annals of the Rheumatic Diseases

Volumn 66, Issue 10, 2007, Pages 1393-1397

  Conti, Fabrizio ^a   Ceccarelli, Fulvia ^a   Marocchi, Elisa ^a   Magrini, Leonardo ^a   Spinelli, Francesco Romana ^a   Spadaro, Antonio ^a   Scrivo, Rossana ^a   Valesini, Guido ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RISK ASSESSMENT; SPONDYLOARTHROPATHY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34848860252     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.073569     Document Type: Article

References (15)

1. Kavanaugh A, Tutuncu Z, Catalan-Sanchez T. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol 2006;18:347-53.
2. van Vollenhoven RF. Switching between biological agents. Clin Exp Rheumatol 2004;22(Suppl):S115-21.
3. Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF. Adalimumab (Humira ) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005;34:353-8.
4. Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007;66:249-52.
5. Hyrich KL, Lunt M, Watson KD, Deborah P, Symmons M, Silman AJ for the British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis. Results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
6. Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005;32:2183-5.
7. Cantini F, Niccoli L, Benucci M, Chindamo D, Nannini C, Olivieri I, et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 2006;55:812- 16.
8. van der Linden SM, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of New York criteria. Arthritis Rheum 1984;27:361-8.
9. Helliwell P, Marchesoni A, Peters M, Barker M, Wright V. A re-evaluation of the osteoarticular manifestations of psoriasis. Br J Rheumatol 1991;30:339-45.
10. Gladman DD. Psoriatic arthritis. Baillieres Clin Rheumatol 1995;9:319-29.
11. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. New approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
12. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20.
13. Fries JF, Spitz P, Kraines RG, Holman HH. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
14. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D for the ASAS Working Group. First update of the International ASAS Consensus Statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
15. Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo R-M. Lack of efficacy of a third tumor necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology 2006;45:1121-4.